Introduction
Lyme Disease (LD) is caused by B. burgdorferi sensu lato (s. l.) and is transmitted by ticks of the genus Ixodes (1, 2) . It is the most common tickborne disease in the US with an incidence of 6 per 100,000, with endemic areas such as Connecticut reaching 111 cases per 100,000 (3) . LD is also frequent in Asia and Europe, particularly in Germany, Austria, Slovenia and Sweden (2, 4) . B. burgdorferi s. l. comprises at least 12 species with B. burgdorferi sensu stricto (Bbu), B. garinii (Bga) and B. afzelii (Baf) being of highest clinical importance (2) . In the US, LD is exclusively caused by Bbu, whereas in Europe all human pathogenic 2 species are found, with Bga and Baf being predominant (2, 5, 6) . LD is an infectious disease occurring in different clinical stages: Early localized infection is indicated by erythema migrans (EM) in approx. 70-90 % of the patients (7) (8) (9) , and early disseminated infection often causes neurological manifestations, such as facial palsy, meningitis, meningoradiculitits or meningoencephalitis (early neuroborreliosis, NB, 2,8,9). The cardinal manifestation of late stage LD in the US is Lyme arthritis (LA), with approx. 70 % of the untreated EM cases developing this syndrome (10, 11) . In Europe, next to arthritis, acrodermatitis chronica atrophicans (ACA) is a frequent late manifestation, and has been associated with Baf (11) .
Currently, diagnosis of LD is generally based on assessment of clinical features in combination with immunologic serum testing, where both, ELISA and a confirming immunoblot are required (12, 13) . However, since in Europe and Asia at least three species are causing LD, there is a substantial variation of immunodominant antigens, which requires the combination of various homologous antigens for effective serodiagnosis (14) (15) (16) . Immunologic evaluation in these areas is therefore complicated, and no consensus has been established yet (12) . Comparably to diagnostic procedures, vaccination strategies directed against LD so far have also been based on proteinaceous antigens: In the 1990s, recombinant vaccines based on OspA were found to be effective (17) , but the production was discontinued, one reason being the high production costs in comparison to early treatment (2) . Another concern raised against this approach was a potential triggering of autoimmune diseases by vaccination with Osps due to a similarity between an immunodominant epitope in OspA and human leukocyte function associated antigen 1 (LFA-1, 18).
In contrast to proteins, information on membrane glycolipids in Borrelia available today is rather scarce. In 1978, a preliminary compositional analysis of lipid extracts of B. hermsii causing relapsing fever (RF) indicated the presence of monoglucosyl-diacylglycerol and acylated as well as non-acylated cholesteryl glucosides (19) . Later, studies on Bbu indicated the presence of complex glycolipids as well, but no chemical analysis was performed (20, 21) . A more recent study identified mono-α-D-galactosyl-diacylglycerol (MGalD) in Bbu, and first data indicated that antibodies present in sera obtained from LD-patients detected this antigen (22) . We and others were recently able to show that Bbu furthermore exhibits cholesteryl 6-O-acyl-β-D-galactopyranoside (ACGal) as well as its non-acylated counterpart, cholesteryl β-Dgalactopyranoside (βCGal) (23, 24) . Patient sera reacted with ACGal more frequently as compared to MGalD (23) , and antibodies could be raised in mice by intraperitoneal injection (24) , indicating that this compound is a strong immunogen.
The aim of this study was to elucidate whether ACGal is a common structure present in the most relevant B. burgdorferi species of clinical importance, and whether it is a specific feature of Borrelia causing Lyme Disease. Furthermore, we aimed at defining the frequency of the occurrence of antibodies against this antigen in patients suffering from Lyme Disease. To this end, we performed a comparative structural analysis of glycolipid fractions of Bbu as well as the two other B. burgdorferi s. l. species of clinical importance, Baf and Bga, in comparison with B. hermsii (Bhe) , the causative agent of relapsing fever. We found ACGal to be present in all B. burgdorferi species tested, whereas Bhe exhibited cholesteryl 6-Oacyl-β-D-glucopyranoside (ACGlc) instead. Antibodies against ACGal could be detected in the majority of patients diagnosed for arthritis or acrodermatitis, and these failed to cross-react with ACGlc. These data demonstrate that ACGal is an abundant, but still highly specific antigen in B. burgdorferi and thus a promising candidate for vaccine development and improvement of serologic methods.
Munich, Germany. B. hermsii (HS1; tick isolate) was purchased from ATCC (Manassas, VA, USA).
Cultivation of Borrelia
Glycerol stocks of Borrelia were stored at -80 °C. 100 µl were transferred to 5 ml BSK-H complete medium containing 6 % rabbit serum (SigmaAldrich, Taufkirchen, Germany). After 3 to 4 days of culture at 34 °C and microaerophilic conditions, viability of bacteria was ensured by darkfield microscopy and cultures were transferred to 50 ml of medium. After culturing for another 4 days, bacteria were transferred to the final volume of 500 ml. Borrelia were harvested by centrifugation at 12,000 x g at 4 °C for 20 min followed by two washing steps with endotoxin-free water (Braun, Melsungen, Germany) under similar conditions. Bacteria were then subjected to analytical and preparative procedures. Sonicates were prepared by suspending dried Borrelia (5 mg) in 5 ml of 0.05 M sodium acetate followed by sonication four times for 2 min. The sonicate then was centrifuged for 3 min at 3,000 x g at 4 °C, and the supernatants were harvested and spun for 30 min at 12,000 x g at 4 °C. The resulting pellet was washed twice with phosphate buffered saline (PBS, Invitrogen/Gibco, Karlsruhe, Germany) and stored at -20 °C.
Cell disintegration and total lipid extraction
Lyophilized Borrelia cells were suspended in 15 ml pyrogen-free water and subsequently disrupted by a sonifier (250 W, Branson, Danbury, CT, using a 5 mm micro tip, output control 6, duty cycle 50 %) 3 times for 5 minutes in ice-cooled water. Fifteen ml n-butanol (LiChrosolv, Merck, Darmstadt, Germany) were added to the suspension and the tube was shaken for 15 min. For phase separation it was centrifuged at 6,200 x g for 1 h at 4 °C and the butanol phase was taken off. The remaining phases (water, interphase and pellet) were extracted again with 15 ml n-butanol. Both butanol phases were united and re-extracted with 15 ml pyrogen-free water. The total lipids were yielded after vacuum evaporation of the butanol phase as an oily solid. 
Analytical Thin Layer Chromatography (TLC) and Preparative Thin Layer Chromatography

Gas-Liquid Chromatography (GLC) and Combined Gas-Liquid Chromatography/Mass Spectroscopy (GLC-MS)
Compositional analysis employing GLC-MS was performed with 100 µg of each sample after mild methanolysis with 1.5 ml of 0.5 M HCl/MeOH for 1 h at 85 °C in sealed ampoules. The liquid was blown off by N 2 and the sample subsequently peracetylated with 1 ml pyridine / acetanhydride (2:1, v/v) for 1 h at 80 °C and concentrated. The chromatography was run on a Hewlett Packard, model 5890 Series II (column: HP-5MS 30m, Agilent, Böblingen, Germany) with a temperature gradient from 150 °C (3 min) to 320 °C at 5 °C/min. The mass spectra were detected and recorded by electron impact and chemical ionization (HP 5989A, Agilent, Böblingen, Germany).
NMR Spectroscopy
The glycolipids and phospholipids were dissolved in 0.5 ml of chloroform-d/methanol-d 4 (9:1, v/v) and DMSO-d 6 , respectively (Cambridge Isotope Laboratories, Andover, MA, USA), and the NMR spectra were recorded in 5-mm high precision NMR tubes (Promochem, Wesel, Germany) at 300 K. Proton ( 1 H) and all proton-detected 2-D NMR spectra were run on a Bruker DRX-600 Avance spectrometer at 600 MHz. Carbon ( 13 C) and distortionless enhancement by polarization transfer (DEPT 135) spectra were measured on a Bruker DPX-360 spectrometer at 90.6 MHz. The chemical shift values were referenced to internal TMS (δ H = 0.00 ppm) or CDCl 3 (δ c = 77.0 ppm). 1 H/ 1 H correlated spectroscopy (COSY), 1 H/ 1 H total correlated spectroscopy (TOCSY), 1 H/ 13 C heteronuclear multiple quantum coherence (HMQC), and 1 H/ 13 C heteronuclear multiple bond connectivity (HMBC) experiments were performed using standard Bruker software (XWinNMR 3.5).
Patient Sera
Sera derived from Patients diagnosed for LD as well as sera derived from controls were provided by B.W. and V.F., Munich, Germany. Serodiagnosis was based on ELISA and subsequent confirmative immunoblotting. In total, 68 samples from patients (20 for EM, 19 for early NB, 14 for ACA and 15 for LA) and 20 samples from healthy controls were tested. Blots were washed with PBS and bands were detected with the ECL-system (Amersham, Braunschweig, Germany) as recommended by the manufacturer's protocol using Hyperfilm ECL-films (Amersham, Braunschweig, Germany). The same procedure was employed for detecting IgM using anti-human IgM-HRP conjugate (Santa Cruz, Palo Alto, USA). For TLC immunoblotting, Borrelia extracts were separated on TLC as described above. The run TLC plate was transferred to a membrane by application of heat employing a published protocol (25) with the following modifications: The dried TLC plate was slowly submersed into transfer buffer (25 mM Tris HCl, pH 10.4, 20 % MeOH) for 10 sec. The plate was gently dried using a soft tissue leaving only a little wetness. The PVDF membrane (Millipore, Bedford, MA) with the same dimensions was put on top and was quickly straightened out with a glass rod. Covered by a glass microfiber sheet (GF/A, Whatman, Brentford, UK), a 150 °C preheated electric iron was placed on the membrane and plate for 30 s. The membrane was peeled off and let dry. The development of the blots was similar as described above for immunoblotting of membranes.
Immunoblotting of Glycolipids
ACGal antibody titer determination
A 96-well plate (nunc maxisorb, Nunc a/s, Roskilde, Denmark) was coated with 50 µl per well of a 30 µg/ml ACGal solution (in 0.1 M Na-HCO 3 , pH 8.2) for 16 h at 4 °C. The plate was washed twice with aqua dest., blocked with 200 µl per well blocking buffer (0.05 M Hepes, 0.15 M NaCl, 10 mg/ml BSA, pH 7.4) and incubated for 1 h at RT. The plate was washed 3 times with 200 µl washing buffer (0.05 M Hepes, 0.15 M NaCl, 1 mg/ml BSA, pH 7.4) and incubated with 100 µl per well of sera diluted in washing buffer for 2 h. After washing (3x) the plate was incubated with 100 µl per well of a 1:1000 dilution of secondary antibody HRP conjugate (rabbit anti-human IgG-HRP, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) in washing buffer for additional 2 h. Following a washing step (3x) the staining was started by addition of 100 µl per well TMB solution (SeramunBlau slow [ELISA], Seramun Diagnostica, Heidese, Germany), incubated in the dark for a few minutes and stopped with 50 µl per well 2 M H 2 SO 4 . The optical density was measured at 450 nm in an ELISA reader (SPECTRA Fluor Plus, Tecan, Crailsheim, Germany). As a cut-off, the mean value of negative samples at the corresponding dilution plus the two-fold standard deviation was used.
Results
Comparative Analysis of Lipid Extracts from Different Borrelia burgdorferi Strains
Bbu, Bga, Baf, and Bhe were grown in BSK-H medium, harvested, and lyophilized as described in the Experimental Procedures section. Butanol extraction yielded 161 mg total lipids for Bbu, 16.6 mg for Bga, 11.3 mg for Baf, as well as 25.0 mg for Bhe, respectively, corresponding to 26.7, 28.6, 24.7, and 28.8 percent of total dry weight (Tab. 1). The total lipids were subjected to TLC in CHCl 3 /MeOH 85:15 (v/v) to separate glycolipids and visualized with mostain (Fig. 1A) . In the lipid extract derived from Bbu, all previously described lipids (23) were detected except for two distinct patterns in the fraction formerly assigned as F4, F4a and F4b (Fig. 1A) . Furthermore, the phospholipid fraction F5 revealed two spots, which were subdivided into fractions F5a and F5b (Fig. 1A  and B) .
The lipid distribution in all three LD strains was homologous, with differences in proportions only (Tab. (Fig. 1) . The major lipid in all three strains was fraction F2. It was identified in Baf and Bga by GLC-MS ( Fig.  2A) , NMR (Fig. 2B) , and MALDI-TOF-MS (not shown) as cholesteryl 6-O-acyl-β-D-galactopyranoside, thus being identical with ACGal formerly identified in Bbu. No significant differences in the fatty acid distribution could be observed since in all three LD strains palmitic acid (16:0) and oleic acid (18:1) dominated. 
Identification of Cholesteryl β-D-Glucopyranoside
(βCGlc) in B. burgdorferi As mentioned above, fraction F4a was not detected previously, potentially since it is present only in trace amounts (Tab. 1) and stains also faintly with sulfuric acid / EtOH, used in the first studies (23). Under conditions used for TLC, α-glycosides possess slightly higher R f -values as compared to β-glycosides; therefore we first considered F4a as cholesteryl α-D-galactopyranoside (αCGal). A comparison of chemically synthesized αCGal standard with F4a derived from Bbu applied to TLC in toluene / EtOH 85:15 (v/v) gave clearly distinct R f values, ruling out αCGal. Next we compared F4a with cholesteryl β
ACGal and MGalD are the only GlycolipidAntigens Recognized by Sera from Patients
One of the major aims of this study was to determine the frequency by which antibodies against Borrelia glycolipids are encountered in patients during LD. Previous studies investigated low numbers of sera, focusing on MGalD (22) or MGalD, ACGal and CGal (23), whereas βCGlc was not investigated before. Therefore, we aimed at elucidating which glycolipids are immunogenic by testing pooled sera. We applied the butanol extracts, which were separated on TLC plates and blotted onto PVDF membranes as described in the Experimental Procedures Section. Membranes were incubated with diluted patient sera, which had been pooled for each clinical stage (EM, NB, ACA and LA, respectively). We did not observe specific recognition of any glycolipid when pooled sera from patients diagnosed with EM or NB were tested (Fig. 4A) . In contrast, pooled sera from patients suffering from ACA exhibited antibodies directed against ACGal and MGalD, whereas sera from patients with LA interacted exclusively with ACGal. No antibodies against βCGal or βCGlc were detected. Based on this finding we focused our further analysis on ACGal and MGalD.
ACGal is the dominant antigen in late stage Lyme Disease
To assess the frequency of antibodies against ACGal and MGalD in patients at different stages of LD, both ACGal and MGalD were tested by dot-blots with the individual sera. To investigate the specificity of antibodies against ACGal, ACGlc from Bhe was included in the analysis. PVDF-membranes were spotted with purified ACGal of all three LD strains investigated, as well as MGalD from Bbu and ACGlc from Bhe. As a positive control, total Borrelia sonicates were employed. Blots were incubated with patient sera and antigen-specific IgG was detected as described in the Experimental Procedures section. Antibodies directed against MGalD were detected in 2 sera from EM patients (10 percent of samples investigated) and 6 sera from patients suffering from late disease (21.1 percent), whereas none of the sera derived from NB patients displayed anti-MGalD antibodies (Fig. 4B and Tab. 3) .
In contrast, IgG directed against ACGal was detected in patients from all groups, including EM and NB (1 out of 20 and 5 out of 19, respectively). Strikingly, 24 out of 29 (82.8 %) patients diagnosed for late disease exhibited antibodies against ACGal, with no apparent differences between patients diagnosed for ACA or LA, respectively (Tab. 3). In every case, antibodies were found against ACGal from all species tested. One of the sera derived from a patient diagnosed for ACA exhibited antibodies against ACGlc from Bhe, while antibodies against ACGal were absent. We exclusively detected anti-glycolipid IgG antibodies, whereas no antibodies of the IgM subtype were found (data not shown). We determined antiACGal antibody titers in sera tested positive for ACGal by dot blot employing an ELISA technique based on adsorption of ACGal to microtiter plates as described in the Experimental Procedures section. Here, the majority of sera derived from patients diagnosed for ACA and LA exhibited antibody titers greater than 1:1000, with two LApatients exhibiting titers of 1:32,000 (Tab. 4).
Discussion
In this study we performed a comparative analysis of glycolipids derived from Borrelia strains causing LD as well as from Bhe causing RF in order to elucidate the potential of these compounds as candidates for vaccine development or for improvement of diagnosis of LD. We found a strikingly similar pattern of glycolipids within Bbu, Bga, and Baf. In particular, ACGal turned out to be the most abundant glycolipid among all strains tested, as it comprises approx. 45 % of glycolipids, 22 % of total lipids, and 6 % of the dry weight. βCGal and MGalD were also found in all strains at comparable levels, and additionally we found that these strains contained βCGlc. However, this glycolipid was found in significantly lower levels when compared to ACGal and βCGal. Since glycolipids isolated from Bhe also predominantly contained cholesterol, we can conclude that the majority of glycolipids present in Borrelia spp., with the exception of MGalD based on diacylglycerol, contain cholesterol. However, in contrast to B. burgdorferi strains, Bhe contained ACGlc and βCGlc, thus exclusively exhibiting cholesterol-containing glycolipids based on glucose. The presence of nonacylated and acylated cholesteryl glucosides in Bhe was postulated before (19) , but data were limited to a compositional analysis lacking connectivity and anomeric configuration.
Sequencing of the Bbu strain B31 genome (27) identified genes encoding for a galactosyltransferase (mgs, BB0454, 28) indicating that these bacteria glycosylate cholesterol from the host (or culture medium) and incorporate it into their membranes. This incorporation of cholesterol obtained from their hosts into glycolipids appears to be a special feature of Borrelia spp., shared only with a few other pathogenic bacteria like Mycoplasma spp. (29, 30) or Helicobacter spp. (31) . However, it has to be pointed out that the anomeric configuration β distinguishes ACGlc isolated from Bhe from the cholesteryl 6-O-acyl-α-Dglucopyranoside found in H. pylori (32) . At this point, we can only speculate why Borrelia exhibit the consistent feature of incorporating cholesterolderivates. It was recently shown that β-glucosylation of host-derived cholesterol by H. pylori protects the bacterium from the host's immune system (33) . Thus, the abundance of glycosylated cholesterol-derivatives among Borrelia spp. may be indicative of a similar mechanism of immune evasion.
We tested sera derived from patients diagnosed for LD at different stages for the presence of antibodies against Borrelia glycolipids focusing on MGalD, ACGal, and, for reasons of testing specificity, ACGlc from Bhe. IgG-antibodies directed against ACGal were found in sera of all LD stages and none of the controls, however, the most striking finding was that during late stages of disease over eighty percent of patients developed antibodies against ACGal reaching titers of up to 1:32,000. These findings also show that ACGal acts as a stronger antigen as compared to MGalD, since only about twenty percent of late stage sera exhibited antibodies against MGalD. This is in excellent agreement with our earlier work (23) . These results furthermore demonstrate that the development of anti-glycolipid antibodies is a feature of late stage LD. In addition, our data furthermore indicate that antibodies against ACGal are highly specific since the structurally closely related glycolipid ACGlc from Bhe was only detected by one serum, which did not contain antiACGal-antibodies. Taken together, this indicates that ACGal is a strong antigen, which is abundant among Borrelia, yet specific for Borrelia causing LD. In contrast, MGalD is not unique to B. burgdorferi s. l. because it is present in Bhe, (19) , other spirochetes (34) , and even numerous vertebrates (35) . Regarding the antigenic epitope in ACGal, the lack of recognition of βCGal and ACGlc by the sera tested indicates that at least the Gal and the fatty acid moiety, either partially or entirely, are important for immunization. This is in agreement with the consideration that the carbohydrate could form the polar head of the lipid jutting out of the membrane while cholesterol and fatty acid form the hydrophilic tail, which is concealed within lipid bilayer.
Our results indicate that ACGal may be a candidate for improving diagnosis of LD as well as vaccination strategies. Regarding the value of testing for ACGal-antibodies in serodiagnosis of LD, the results point at a promising sensitivity particularly in late stages of disease combined with an outstanding specificity. Thus, including ACGal into an antigen panel for serodiagnosis of LD may increase test reliability considerably, in particular since ACGal, as we show here, is abundant among the three clinically most relevant B. burgdorferi s. l. species. Presence of ACGal in the recently described species B. spielmanii, remains to be investigated, however, so far this agent has been detected in a low number of cases with EM but not in disseminated disease (5). Furthermore, our observations that ACGal is 1) a strong antigen, 2) abundant among B. burgdorferi substrains and 3) induces highly specific antibodies, together with the previous observation that administration of ACGal induces antibodies (24) , make it a highly promising vaccine candidate. In theory, immunization strategies based on ACGal, as compared to approaches based on proteinacous antigens, would have the advantage that ACGal as a major constituent of the membrane of the bacteria is unlikely to be differentially expressed by the bacteria during different stages of disease, as has been shown for several other antigens, such as Osps. Also, as of yet there are no reports on host molecules bearing significant homologies to ACGal. In the case of LYMErix TM , the potential development of autoantibodies against LFA-1 due to homologies with OspA was one of the reasons, which led to the withdrawal of this vaccine from the market (18, 36) . However, since glycosylated cholesterol derivates so far have been described in bacteria, fungi, plants and slime molds (30, 31, 37) only, the development of antibodies during ACGalvaccination cross-reacting with host tissues is unlikely. Finally, we have shown previously that ACGal, in contrast to MGalD (38), does not induce pro-inflammatory cytokines (23) indicating that adverse acute events during administration of this compound would also be highly unlikely.
Taken together, our data define acylated cholesterol glycosides as a major constituent of Borrelia lipid membranes, with B. burgdorferi sensu lato exhibiting ACGal exclusively. Since we detected antibodies against ACGal in the majority of patients suffering from late stage LD we propose that this compound is a useful tool for improving LD diagnostics as well as a promising vaccine candidate. 
Figure Legends
